NCT07226986 2026-04-16
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Phase 1/2 Recruiting
Clinical Trials
16 trialsNCT05849298 2026-04-13
PSMACare
Novartis
Phase 2 Active not recruiting
NCT06894511 2026-04-08
PSMAndARPI
Novartis
Phase 2 Active not recruiting
NCT07047118 2026-04-08
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Active not recruiting
NCT06785636 2026-04-07
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT05114746 2026-04-01
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Active not recruiting
NCT04689828 2026-03-23
PSMAfore
Novartis
Phase 3 Active not recruiting
NCT04720157 2026-03-11
PSMAddition
Novartis
Phase 3 Active not recruiting
NCT06004661 2026-03-06
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Novartis
Phase 2 Recruiting
NCT06514521 2025-12-30
Post Marketing Study on Pluvicto in Korea
Novartis
Recruiting
NCT05682443 2025-12-02
PRESERVE-006
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT06516510 2025-09-25
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Blue Earth Therapeutics Ltd
Phase EARLY_PHASE1 Terminated
NCT05803941 2025-04-24
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Novartis
Phase 4 Recruiting
NCT03511664 2025-01-13
VISION
Endocyte
Phase 3 Completed
NCT04825652 2023-01-13
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
Advanced Accelerator Applications
No longer available
NCT03042312 2021-03-24
RESIST-PC
Endocyte
Phase 2 Terminated